Rani Therapeutics Holdings (RANI) Free Cash Flow (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Free Cash Flow of -$6.5 million for Q1 2026, up 20.59% year-over-year from -$5.4 million in Q1 2025, and down 2376.92% quarter-over-quarter from $286000.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Free Cash Flow (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$6.5 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 20.59% year-over-year to -$6.5 million; the TTM figure through Mar 2026 stood at -$17.1 million (up 50.46% YoY), while the FY2025 annual figure was -$18.8 million, up 47.43% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$6.5 million, down from $286000.0 in the prior quarter.
- The five-year high for Free Cash Flow was $286000.0 in Q4 2025, with the low at -$15.2 million in Q4 2022.
- The 5-year median for Free Cash Flow is -$9.4 million (2024), against an average of -$9.4 million.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow slumped 134.15% in 2022, then surged 103.29% in 2025.
- Rani Therapeutics Holdings' Free Cash Flow stood at -$15.2 million in 2022, then rose by 19.22% to -$12.2 million in 2023, then rose by 29.07% to -$8.7 million in 2024, then soared by 103.29% to $286000.0 in 2025, then plunged by 2376.92% to -$6.5 million in 2026.
- Business Quant data shows RANI's Free Cash Flow at -$6.5 million in Q1 2026, $286000.0 in Q4 2025, and -$5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | -9.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.06 Mn |
| Jun 30, 2026 | -9.06 Mn |
| Mar 31, 2026 | -6.51 Mn |
| Mar 31, 2026 | -6.51 Mn |
| Dec 31, 2025 | 286,000.00 |
| Dec 31, 2025 | 286,000.00 |
| Sep 30, 2025 | -5.10 Mn |
| Sep 30, 2025 | -5.10 Mn |
| Jun 30, 2025 | -5.79 Mn |
| Jun 30, 2025 | -5.79 Mn |
| Mar 31, 2025 | -8.20 Mn |
| Mar 31, 2025 | -8.20 Mn |
| Dec 31, 2024 | -8.69 Mn |
| Dec 31, 2024 | -8.69 Mn |
| Sep 30, 2024 | -8.54 Mn |
| Sep 30, 2024 | -8.54 Mn |
| Jun 30, 2024 | -9.12 Mn |
| Jun 30, 2024 | -9.12 Mn |
| Mar 31, 2024 | -9.42 Mn |
| Mar 31, 2024 | -9.42 Mn |